As the government’s oldest consumer protection agency, the FDA has long butted up against drugmakers, activists and politicians. But undermining its work could be harmful to patient health and safety.
Academic rigor, journalistic flair
Articles on Texas ruling on mifepristone
Displaying all articles
The Supreme Court’s ruling on mifepristone keeps the drug accessible for now, but its future is still in limbo.
Many people wonder how courts can rule in contradictory ways. But it happens relatively frequently.
If the ruling to reverse the use of mifepristone stands, it will not only severely restrict abortion access for women throughout the US – it will have far-reaching effects on health care.
Top contributors
-
Associate Professor of Obstetrics, Gynecology and Gynecologic Surgery, University of California, San Francisco
-
Associate Professor of Legal Studies and Political Science, UMass Amherst
-
Professor of Law, George Washington University
-
Professor of Law, University of Virginia
-
Professor of Law, Wake Forest University
